There is a refreshing wind sweeping through the profession. The modern prescriber-of-drugs has become disenchanted with empiricism in therapeutics. He is demanding to see proper credentials on all new drugs; testimonial and anecdotal evidence will not suffice. The busy physician is frequently immersed in the bountiful blessings streaming from the pharmaceutical cornucopia; he requires information that is concise, factual, and easily accessible. This urgent requirement has been recognized, and help is at hand. Several sources are now available.
Heading the list is New Drugs. This strongly bound, handy paperback is crammed full of pertinent data on 1,290 single entity drugs that have been marketed within the past ten years in the United States. At $4 ($3 house officers and medical students), it is the book bargain of the year. Each of the 50 chapters begins with a general discussion of a class of drugs; this is followed by a concise
Moser RH. New Drugs. Arch Intern Med. 1967;120(2):249. doi:10.1001/archinte.1967.00300020121018
Best of JAMA Network 2022
Customize your JAMA Network experience by selecting one or more topics from the list below.